Skip to content
Mesothelioma Cancer Help

Mesothelioma Diagnosis

What Is a Tumor Marker in Mesothelioma Diagnosis?

A tumor marker is a substance, often a protein or other measurable biological feature, found in blood or tissue that helps support—but does not replace—a pathologist’s tissue-based diagnosis.

Key takeaways

  • A tumor marker is often a protein or other measurable biological feature in blood or tissue that may signal cancer activity [1] .
  • No single blood test diagnoses mesothelioma; biopsy with immunohistochemistry is usually central to diagnosis [2] .
  • SMRP is FDA-cleared under a 2007 Humanitarian Device Exemption for monitoring certain previously diagnosed patients, not screening or stand-alone diagnosis [7] .
  • Tissue markers BAP1 and MTAP loss can support malignancy in the right pathology context as part of a panel [6] .
  • NCI and ACS do not recommend serum markers for routine population screening [2] [3] .

If you or a family member has been told that doctors are looking for tumor markers as part of a mesothelioma workup, the term can be confusing. This article is written for patients, family members, and caregivers who want a clearer picture of what tumor markers can and cannot do in mesothelioma care.

It covers the main blood markers studied to date, the tissue-based markers pathologists use during biopsy review, and how these results fit into the broader diagnostic process.

What a tumor marker is, in plain language

A tumor marker is any substance produced by cancer cells, or by other cells of the body in response to cancer or certain noncancerous conditions, that can be measured to support diagnosis or monitoring [1] . The National Cancer Institute groups tumor markers into serum markers measured in blood and tissue markers detected in biopsy material by methods such as immunohistochemistry [4] .

In mesothelioma care, both kinds appear, but they play different roles.

Serum (blood) markers

These proteins and related substances are measured in a blood sample. They can sometimes be elevated in people with mesothelioma, but they can also be elevated for other reasons.

Tissue markers, or IHC

These markers are detected by staining a small piece of tumor tissue removed during biopsy. Tissue markers are commonly central to mesothelioma diagnosis.

Tumor markers can support diagnosis, help distinguish mesothelioma from cancers that look similar under the microscope, track treatment response, and watch for return of disease after treatment [5] . None of these uses turns a single number into a final answer; they are inputs to a clinical picture built by an oncologist and a pathologist.

Sensitivity is the percentage of people with a disease who have a positive test result. Specificity is the percentage of people without the disease who have a negative test result. For mesothelioma, serum markers studied so far tend to have moderate sensitivity and moderate to good specificity, which is part of why they are not used for screening [3] [5] .

Why mesothelioma is difficult to diagnose from blood tests alone

Mesothelioma is a rare cancer of the thin lining of the lungs, abdomen, or heart that usually appears decades after asbestos exposure, and no blood-based tumor marker has the sensitivity and specificity needed to diagnose it on its own [2] [3] .

The National Cancer Institute’s clinical reference for malignant mesothelioma states that pathologic examination of tissue, supported by immunohistochemistry, is commonly central to diagnosis [2] . Imaging findings can also be mistaken for other lung or abdominal conditions, which is part of why blood markers alone are insufficient.

  • Overlap with other diseases. Markers such as mesothelin can be elevated in ovarian cancer, pancreatic cancer, some lung adenocarcinomas, and benign conditions such as kidney failure [3] [5] .
  • Imperfect sensitivity. A normal level does not rule out mesothelioma, especially in early-stage disease or in the sarcomatoid subtype [5] [6] .
  • No proven screening benefit. The American Cancer Society notes that there is no recommended blood-based screening test for mesothelioma in people who have been exposed to asbestos [3] .

Serum tumor markers studied in mesothelioma

Three serum tumor markers have received the most attention in mesothelioma research: mesothelin, often measured as SMRP, osteopontin, and fibulin-3. Available markers may help support a clinical picture in selected contexts, but they do not replace tissue-based diagnosis [5] [6] .

Mesothelin and SMRP (soluble mesothelin-related peptides)

Mesothelin is a protein normally expressed in small amounts by mesothelial cells that line body cavities; in epithelioid mesothelioma it is often overexpressed, and a fragment called soluble mesothelin-related peptides can be measured in blood [3] [5] .

The MESOMARK assay, an SMRP test, received a Humanitarian Device Exemption from the U.S. Food and Drug Administration in 2007. Under that exemption, it is cleared to help monitor certain patients already diagnosed with epithelioid or biphasic mesothelioma, not to screen healthy people or to make a first diagnosis [7] .

  • SMRP levels can rise with reduced kidney function and with other cancers, which can produce false-positive results [3] [5] .
  • An elevated SMRP value supports the need for further evaluation; a normal value does not rule out mesothelioma.
  • The 2007 HDE is for serial monitoring of certain previously diagnosed epithelioid or biphasic disease, not first-line diagnosis or screening [7] .

Osteopontin

Osteopontin is a protein involved in tissue remodeling and inflammation that has been studied as a serum marker for mesothelioma, but it is not an established stand-alone diagnostic test [5] [6] . Later studies found that osteopontin is also elevated in many other inflammatory and cancerous conditions, which limits its specificity. It is not in routine clinical use for mesothelioma diagnosis in most centers today.

Fibulin-3

Fibulin-3 is a protein in the extracellular matrix that was reported in 2012 to be elevated in the blood and pleural fluid of people with pleural mesothelioma, but follow-up studies have produced mixed results [6] [8] . Fibulin-3 is still considered investigational or supportive in research contexts rather than a standard stand-alone clinical diagnostic test.

Tissue-based markers used during biopsy review

Tissue-based markers, applied by a pathologist using immunohistochemistry on biopsy material, commonly carry the most diagnostic weight in mesothelioma diagnosis [6] . The 2018 pathology guideline recommends using a panel of at least two markers that are typically positive in mesothelioma and at least two that are typically positive in the most likely competing diagnosis, rather than relying on any single stain [6] .

Positive markers: calretinin, WT1, CK5/6, D2-40

Common tissue markers that may support epithelioid mesothelioma diagnosis
Marker What it may suggest when positive
CalretininMesothelial origin; positive in most epithelioid mesotheliomas.
WT1 (Wilms tumor 1)Mesothelial origin; helps distinguish from lung adenocarcinoma.
CK5/6 (cytokeratin 5/6)Mesothelial or squamous origin.
D2-40 (podoplanin)Mesothelial origin and lymphatic marker.

No single positive stain proves mesothelioma. Pathologists interpret the panel as a whole, together with the patient’s clinical and imaging picture [6] .

Loss-of-expression markers: BAP1 and MTAP

Two markers, BAP1 and MTAP, can help distinguish malignant mesothelial disease from benign reactive change because their absence on tissue staining may support malignancy in the right pathology context [6] . Loss of BAP1 nuclear staining is seen in a substantial fraction of mesotheliomas and is rare in benign mesothelial proliferations. Loss of MTAP staining correlates with deletion of the CDKN2A gene, a change frequently found in mesothelioma but uncommon in benign mesothelial conditions.

These markers are not stand-alone diagnostic tests. Pathologists interpret BAP1, MTAP, and other stains as part of a broader panel, especially when the question is whether tissue represents benign change or malignancy [6] .

How tumor markers fit into the broader diagnostic process

A typical diagnostic workup for suspected mesothelioma combines imaging, fluid sampling, biopsy, immunohistochemistry, and, where used, serum markers, with biopsy and immunohistochemistry commonly carrying the most diagnostic weight [2] [3] . Tumor markers play a supporting role at several points but do not by themselves determine the diagnosis.

Common steps doctors may discuss

The usual diagnosis path

Not every person will need every step. Your care team can explain which steps fit your situation.

  1. 01
    Imaging

    A chest X-ray often shows pleural thickening or fluid; CT, MRI, or PET-CT may characterize suspected disease more fully.

  2. 02
    Fluid sampling

    If pleural or peritoneal fluid is present, doctors may draw a sample and examine it for cancer cells.

  3. 03
    Biopsy

    A tissue biopsy commonly provides material that pathologists need for microscopic review.

  4. 04
    Pathology with immunohistochemistry

    The pathologist applies a panel of stains and integrates the findings with clinical context.

  5. 05
    Serum markers, where used

    Markers such as SMRP may be drawn at diagnosis to establish a baseline and repeated during follow-up.

This staged approach is why a single elevated or normal blood marker rarely changes a diagnosis on its own. The clinical picture and the tissue findings carry the most weight. For a broader overview, see the site’s mesothelioma diagnosis guide.

Questions patients commonly ask their care team about tumor markers

The questions below are examples that some patients and families bring to clinic visits. They are not a substitute for a conversation with a qualified medical professional, and individual situations vary.

Understanding results

  • Which tumor markers, if any, were measured in this situation, and what do the results mean specifically?
  • Are tumor markers being used to help with the initial diagnosis, to monitor response to treatment, or both?
  • If the SMRP level is elevated, what other conditions could explain it?

Understanding tissue review

  • How were the tissue markers on the biopsy interpreted, and did they include BAP1 and MTAP?
  • If the SMRP level is normal, does that change the certainty of the diagnosis?
  • Will tumor markers be repeated over time, and how will changes be interpreted?

Writing these down before an appointment can make a complicated conversation easier to follow.

Frequently Asked Questions

Is there a blood test that can diagnose mesothelioma?

No single blood test diagnoses mesothelioma. The American Cancer Society and the National Cancer Institute state that serum tumor markers such as SMRP can support a diagnosis but cannot replace tissue biopsy. Mesothelioma diagnosis commonly depends on examining biopsy tissue under a microscope, usually with immunohistochemistry stains, alongside imaging and clinical history.

What does an elevated mesothelin or SMRP level mean?

An elevated mesothelin or SMRP level means that the protein is at a higher than usual concentration in the blood. It can occur with epithelioid mesothelioma, ovarian or pancreatic cancer, some lung cancers, and reduced kidney function. Elevated SMRP is a reason for further evaluation by a clinician, not a diagnosis by itself.

Should tumor markers be used to screen asbestos-exposed workers?

Major public cancer information from the American Cancer Society and the National Cancer Institute does not recommend routine blood-based screening for mesothelioma in asymptomatic people with asbestos exposure. Available markers lack the sensitivity and specificity needed for population screening. People with significant asbestos exposure can talk with a clinician about symptom monitoring and whether imaging or other evaluation is appropriate for their situation.

What are BAP1 and MTAP, and why do pathologists check for them?

BAP1 (BRCA1-associated protein 1) and MTAP (methylthioadenosine phosphorylase) are proteins whose loss in tissue staining can support malignancy in the right pathology context, especially when a pathologist is distinguishing mesothelioma from benign reactive change. They are interpreted as part of a broader diagnostic panel, not as stand-alone diagnostic tests.

Conclusion

A tumor marker in mesothelioma diagnosis is a measurable substance or tissue feature, often a protein, used to support but not replace the clinical and pathologic workup [1] [2] . Serum markers such as mesothelin and SMRP, osteopontin, and fibulin-3 have been studied widely; SMRP is the only one listed here with an FDA Humanitarian Device Exemption for monitoring certain previously diagnosed patients, and that clearance is not for making an initial diagnosis on its own [7] .

Tissue-based immunohistochemistry, including a balanced panel of positive markers and loss-of-expression markers such as BAP1 and MTAP, is commonly central to the modern diagnostic workup [6] . Conversations about individual results belong with the medical team that knows the full clinical picture.

Sources

  1. National Cancer Institute. Definition of tumor marker. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tumor-marker ↩
  2. National Cancer Institute. Malignant Mesothelioma Treatment (PDQ), Health Professional Version. https://www.cancer.gov/types/mesothelioma/hp/mesothelioma-treatment-pdq ↩
  3. American Cancer Society. Tests for Malignant Mesothelioma. https://www.cancer.org/cancer/types/malignant-mesothelioma/detection-diagnosis-staging/how-diagnosed.html ↩
  4. National Cancer Institute. Definition of immunohistochemistry. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immunohistochemistry ↩
  5. National Cancer Institute. Tumor Markers Fact Sheet. https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet ↩
  6. Husain AN, Colby TV, Ordonez NG, et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma. Archives of Pathology and Laboratory Medicine, 2018;142(1):89-108. DOI: 10.5858/arpa.2017-0124-RA. https://meridian.allenpress.com/aplm/article/142/1/89/65476 ↩
  7. U.S. Food and Drug Administration. MESOMARK Humanitarian Device Exemption HDE H060004, Summary of Safety and Probable Benefit. https://www.accessdata.fda.gov/cdrh_docs/pdf6/H060004b.pdf ↩
  8. Pass HI, Levin SM, Harbut MR, et al. Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma. New England Journal of Medicine, 2012;367(15):1417-1427. DOI: 10.1056/NEJMoa1115050. https://www.nejm.org/doi/full/10.1056/NEJMoa1115050 ↩

Last reviewed: 2026-05-21

Medical Disclaimer

This page is for informational purposes only and is not medical advice. It does not diagnose mesothelioma, rule mesothelioma in or out, or recommend testing or treatment. Tumor marker results cannot confirm or rule out mesothelioma by themselves. If you have symptoms, asbestos exposure, or questions about test results, speak with a qualified medical professional and do not delay medical evaluation because a blood marker is normal or elevated.

Editorial information

Written by the Editorial Team, Mesothelioma Information Editor. Last reviewed: 2026-05-21. This educational page preserves cautious source-backed language for patient and family conversations.

Source standards

This page cites public medical and scientific sources, including NCI, ACS, FDA records, pathology guidance, and peer-reviewed research.